Intec Pharma Ltd. (NTEC) Hits New 12-Month High at $7.10
Intec Pharma Ltd. (NASDAQ:NTEC) reached a new 52-week high during trading on Wednesday . The stock traded as high as $7.10 and last traded at $7.15, with a volume of 36,010 shares traded. The stock had previously closed at $6.80.
Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th. Roth Capital set a $10.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research report on Thursday, August 10th. ValuEngine downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. Finally, Maxim Group set a $9.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research report on Wednesday, May 24th.
The firm’s market capitalization is $97.54 million. The company has a 50 day moving average of $5.88 and a 200-day moving average of $5.41.
A hedge fund recently raised its stake in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 522,200 shares of the biotechnology company’s stock after acquiring an additional 25,000 shares during the period. Migdal Insurance & Financial Holdings Ltd. owned 3.80% of Intec Pharma worth $2,977,000 at the end of the most recent reporting period. 16.41% of the stock is currently owned by hedge funds and other institutional investors.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.